Momentum improving; Symposia and R&D investments affecting margin
Year-to-date September 2010: Reported revenue down 0.6% to EUR 423.3 million (CER -5.9%) Sales trend slightly impro…
Year-to-date September 2010: Reported revenue down 0.6% to EUR 423.3 million (CER -5.9%) Sales trend slightly impro…
. - Growth in line with market despite deferred scanner revenues and unfavorable country mix - Reported revenue growth…
. - Revenue growth in Q1 at constant exchange rates (CER) minus 9% at EUR 147.0 million - Reported revenue growth minu…
At the 33rd IDS (International Dental Show), Nobel Biocare will globally launch its innovative state-of-the-art NobelPro…
. - Revenue growth at constant exchange rates (CER) minus 4% at EUR 619.2 million - Change in commercial approach in Q…
Nobel Biocare announced today that it has signed an agreement to buy 100% of BioCad Medical Inc., a leading developer of…